FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD
Facultad
Centro de Investigación Biomédica en Red de Cáncer
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Cáncer (31)
2024
-
Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers
British Journal of Surgery, Vol. 111, Núm. 3
-
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
Breast Cancer Research and Treatment
2023
-
Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response
Frontiers in Immunology, Vol. 14
-
Chromatin insulation orchestrates matrix metalloproteinase gene cluster expression reprogramming in aggressive breast cancer tumors
Molecular Cancer, Vol. 22, Núm. 1
-
Evaluation of triple negative breast cancer with heterogeneous immune infiltration
Frontiers in Immunology, Vol. 14
-
Genome-wide methylation profiling identifies a novel gene signature for patients with synchronous colorectal cancer
British Journal of Cancer, Vol. 128, Núm. 1, pp. 112-120
-
Impact of the COVID-19 Pandemic on Cancer Diagnosis in Madrid (Spain) Based on the RTMAD Tumor Registry (2019–2021)
Cancers, Vol. 15, Núm. 6
-
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 1, pp. 67-80
-
Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)
Cancer Treatment and Research Communications, Vol. 37
2022
-
Biallelic germline mutations in MAD1L1 induce a syndrome of aneuploidy with high tumor susceptibility
Science Advances, Vol. 8, Núm. 44
-
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
BMC Cancer, Vol. 22, Núm. 1
-
Recurrent NOMO1 Gene Deletion Is a Potential Clinical Marker in Early-Onset Colorectal Cancer and Is Involved in the Regulation of Cell Migration
Cancers, Vol. 14, Núm. 16
-
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer
Cancer research, Vol. 82, Núm. 24, pp. 4670-4679
2021
-
Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses
Gut, Vol. 70, Núm. 2, pp. 319-329
-
Epstein–Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report
Frontiers in Immunology, Vol. 12
-
Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer
European Journal of Cancer, Vol. 148, pp. 134-145
-
Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status
Frontiers in Oncology, Vol. 11
2020
-
Combined MEK and PI3K/p110β inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features
Cancer Research, Vol. 80, Núm. 4, pp. 843-856
-
Enhancing global access to cancer medicines
CA Cancer Journal for Clinicians, Vol. 70, Núm. 2, pp. 105-124
-
Mutations in non-tumoral human urothelium: Disease prelude or epilogue?
Bladder Cancer, Vol. 6, Núm. 3, pp. 249-252